Generex Biotechnology Corp., of Miramar, Fla., completed its acquisition of 51 percent of New York-based Olaregen Therapeutix Inc. for $400,000 up front plus $11.6 million in milestones. Olaregen is preparing to launch Excellagen, a wound conforming gel matrix.